AI Article Synopsis

  • Researchers developed two series of new N-hydroxybenzamides that effectively inhibit histone deacetylase 2 (HDAC2), showing strong potential as anticancer agents.
  • The new compounds exhibited significantly lower IC values (in sub-micromolar range) and were up to 4 times more cytotoxic in human cancer cell lines compared to a known HDAC inhibitor (SAHA).
  • Binding experiments revealed that these compounds have a stronger affinity for the active site of HDAC2 than SAHA, indicating their potential for further development as more effective HDAC inhibitors.

Article Abstract

In our search for novel small molecules targeting histone deacetylases, we have designed and synthesized two series of novel N-hydroxybenzamides incorporating 2-oxoindolines (4a-g, 6a-g). Biological evaluation showed that these benzamides potently inhibited HDAC2 with IC values in sub-micromolar range. In three human cancer cell lines the synthesized compounds were up to 4-fold more cytotoxic than SAHA. Docking experiments indicated that the compounds tightly bound to HDAC2 at the active binding site with binding affinities much higher than that of SAHA. Our present results demonstrate that these novel and simple N-hydroxybenzamides are potential for further development as anticancer agents and further investigation of similarly simple N-hydroxybenzamides should be warranted to obtain more potent HDAC inhibitors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioorg.2017.02.002DOI Listing

Publication Analysis

Top Keywords

novel n-hydroxybenzamides
8
n-hydroxybenzamides incorporating
8
simple n-hydroxybenzamides
8
novel
4
incorporating 2-oxoindoline
4
2-oxoindoline unexpected
4
unexpected potent
4
potent histone
4
histone deacetylase
4
deacetylase inhibitory
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!